Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748501 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Sangamo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00748501 is a Phase 2 study that has completed, run by Sangamo Therapeutics. The registered enrollment target is 45 participants.
The verdict
NCT00748501, a Phase 2 study, has completed, sponsored by Sangamo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effects of the investigational drug, SB-509 on progression of the disease in subjects with ALS
Interventions
- DRUG SB-509
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748501
The ClinicalTrials.gov registry entry for NCT00748501 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB-509 is the first listed.
NCT00748501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00748501 about?
NCT00748501 is a clinical study titled "Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)". The purpose of the study is to evaluate the effects of the investigational drug, SB-509 on progression of the disease in subjects with ALS
What is the current status of trial NCT00748501?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2008-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00748501?
The interventions under investigation include: SB-509 (DRUG).
Who is sponsoring clinical trial NCT00748501?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.